Introducing HARMONY PLUS: a second public-private partnership within the HARMONY Alliance, launched at 6 October 2020.
HARMONY and HARMONY PLUS, two ongoing public-private partnerships within the HARMONY Alliance, are utilizing the HARMONY Big Data Platform to improve outcomes for patients with blood cancers
HARMONY PLUS will build up on the success of HARMONY, which is currently using the power of Big Data to speed up the development of improved treatments and more effective strategies for patients with blood cancer. In addition to expanding the focus to other hematologic malignancies that were not initially covered in HARMONY, HARMONY PLUS Integrated Services will boost the power of Big Data by collaborating with other international big data initiatives and expanding access. New Artificial Intelligence (AI) techniques will be applied to enhance analytical capabilities and increase the accuracy of the results. By adapting the platform and tools to be used by hospitals and clinicians to improve patient outcomes, HARMONY PLUS aims to bring the results to where the patient is.
HARMONY PLUS focus: Myeloproliferative (MPN) disorders and other Hematological Malignancies; Chronic Myeloid Leukemia (CML), Polycythaemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis; Hodgkin’s Lymphoma, Waldenström Macroglobulinaemia and other rare blood cancers.
HARMONY focus: Acute Lymphoblastic Leukemia (ALL) | Acute Myeloid Leukemia (AML) | Chronic Lymphocytic Leukemia (CLL) | Multiple Myeloma (MM) | Myelodysplastic Syndromes (MDS) | Non-Hodgkin Lymphoma (NHL) | Pediatric Hematologic Malignancies
Read the one-pager about HARMONY PLUS, including background information >
View the animated HARMONY PLUS introduction, showing its objectives and structure >
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
